{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:19Z","timestamp":1793146639642,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Metastatic breast cancer (MBC) remains a major clinical challenge despite recent advances in HER2-targeted therapies such as trastuzumab deruxtecan (T-DXd). While clinical trials have demonstrated its efficacy, concerns about treatment-emergent toxicities persist, highlighting the need for real-world pharmacovigilance to capture a broader spectrum of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed reports from the US FDA Adverse Event Reporting System (FAERS, 2004\u20132024), including trastuzumab deruxtecan reports recorded since its market introduction in 2019. Disproportionality analyses were performed to identify potential AE signals. Time-to-onset distributions were assessed, and a clinical prioritization score was developed to rank AEs based on signal strength, frequency, mortality, and classification as important or designated medical events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Disproportionality analyses revealed significant AE signals associated with T-DXd across multiple organ systems, including injury and procedural complications, respiratory, gastrointestinal, and social circumstances. Time-to-onset analysis revealed substantial heterogeneity in the timing of T-DXd\u2013associated AEs. Early-onset events included dyspnea and eye disorders, whereas cardiac and nervous system toxicities showed delayed onset. Among twelve high-priority AEs, peritonitis received the highest priority scores (scores\u00a0=\u00a011). Interstitial lung disease demonstrated the most prominent disproportionality signal. Several other pulmonary-related events, including pneumonitis, pulmonary fibrosis, and pulmonary toxicity, also ranked as high priority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study highlights respiratory and gastrointestinal toxicities as major risks associated with T-DXd in metastatic breast cancer. Careful monitoring, early intervention, and patient education are essential to balance benefits and risks, while future research should focus on molecular mechanisms to enable precision medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000004702","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:01:11Z","timestamp":1769011271000},"page":"9483-9493","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Mapping adverse events and monitoring priorities for trastuzumab deruxtecan use in metastatic breast cancer"],"prefix":"10.1097","volume":"112","author":[{"given":"Yilong","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"},{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcheng","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuda","family":"Huoshen","sequence":"additional","affiliation":[{"name":"School of Stomatology, Southwest Medical University, Luzhou, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peifen","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"She","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"},{"name":"Medical College, Guangxi University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songsong","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Qiu","sequence":"additional","affiliation":[{"name":"School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaolu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-9772","authenticated-orcid":false,"given":"Qingmo","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"R2-20260424","doi-asserted-by":"crossref","first-page":"104508","DOI":"10.1016\/j.breast.2025.104508","article-title":"Sarcopenia in patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"82","author":"Jang","year":"2025","journal-title":"Breast"},{"key":"R3-20260424","doi-asserted-by":"crossref","first-page":"4278\u201388","DOI":"10.1002\/cncr.33102","article-title":"Novel HER2-targeted therapies for HER2-positive metastatic breast cancer","volume":"126","author":"Kunte","year":"2020","journal-title":"Cancer"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"5097\u2013108","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R5-20260424","doi-asserted-by":"crossref","first-page":"173\u201385","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.3390\/cancers17121911","article-title":"Trastuzumab deruxtecan in previously treated HER2-low metastatic breast cancer: real-world multicentric study in the portuguese population","volume":"17","author":"Soares Miranda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"501\u201308","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"986\u201396","DOI":"10.1002\/cpt.2291","article-title":"Exposure-response relationships in patients with HER2-positive metastatic breast cancer and other solid tumors treated with trastuzumab deruxtecan","volume":"110","author":"Yin","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"9\u201320","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"2108\u201316","DOI":"10.1200\/JCO.22.02447","article-title":"US food and drug administration approval summary: fam-trastuzumab deruxtecan-nxki for human epidermal growth factor receptor 2-low unresectable or metastatic breast cancer","volume":"41","author":"Narayan","year":"2023","journal-title":"J Clin Oncol"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"2968\u201377","DOI":"10.1002\/cncr.35349","article-title":"The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and\/or pneumonitis: a systematic review and single-arm meta-analysis","volume":"130","author":"Li","year":"2024","journal-title":"Cancer"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"1539\u201348","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"1655\u201368","DOI":"10.2147\/DDDT.S508773","article-title":"A systematic review of mechanisms, incidence, and management of trastuzumab deruxtecan induced ILD\/Pneumonitis in solid tumors","volume":"19","author":"Liao","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"105082","DOI":"10.1016\/j.esmoop.2025.105082","article-title":"Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial","volume":"10","author":"Hu","year":"2025","journal-title":"ESMO Open"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"102865","DOI":"10.1016\/j.ctrv.2024.102865","article-title":"Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis","volume":"132","author":"Schettini","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"3079\u201388","DOI":"10.1111\/cas.16234","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer","volume":"115","author":"Iwata","year":"2024","journal-title":"Cancer Sci"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"428\u201334","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the food and drug administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"R19-20260424","doi-asserted-by":"crossref","first-page":"1010\u201321","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"796\u2013803","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R21-20260424","doi-asserted-by":"crossref","first-page":"539\u201346","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20260424","doi-asserted-by":"crossref","first-page":"57\u201369","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"R23-20260424","doi-asserted-by":"crossref","first-page":"1427\u201337","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States food and drug administration adverse event reporting system events for vinca alkaloids: comparing vinorelbine and vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"R24-20260424","doi-asserted-by":"crossref","first-page":"e0326216","DOI":"10.1371\/journal.pone.0326216","article-title":"The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis","volume":"20","author":"Guo","year":"2025","journal-title":"PLoS One"},{"key":"R25-20260424","article-title":"Pharmacovigilance-based identification and mechanistic exploration of periodontitis-related drugs","author":"Huoshen","year":"2025","journal-title":"J Clin Periodontol"},{"key":"R26-20260424","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN guideline","volume":"10","author":"Riaz","year":"2025","journal-title":"Prem J Sci"},{"key":"R27-20260424","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"R28-20260424","doi-asserted-by":"crossref","first-page":"105\u201317","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"R29-20260424","doi-asserted-by":"crossref","first-page":"1830\u201336","DOI":"10.1111\/cas.13087","article-title":"Drug induced interstitial lung disease in oncology phase I trials","volume":"107","author":"Yonemori","year":"2016","journal-title":"Cancer Sci"},{"key":"R30-20260424","doi-asserted-by":"crossref","first-page":"1063\u201371","DOI":"10.1007\/s10147-015-0834-3","article-title":"Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study","volume":"20","author":"Osawa","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"R31-20260424","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"R32-20260424","doi-asserted-by":"crossref","first-page":"539\u201346","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"R33-20260424","doi-asserted-by":"crossref","first-page":"1873\u201381","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-erbb2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol"},{"key":"R34-20260424","doi-asserted-by":"crossref","first-page":"4636\u201345","DOI":"10.1111\/cas.14686","article-title":"Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys","volume":"111","author":"Kumagai","year":"2020","journal-title":"Cancer Sci"},{"key":"R35-20260424","doi-asserted-by":"crossref","first-page":"2281\u201388","DOI":"10.1158\/1078-0432.CCR-05-2291","article-title":"Analysis of c-ErbB1\/epidermal growth factor receptor and c-ErbB2\/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer","volume":"12","author":"Merrick","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R36-20260424","doi-asserted-by":"crossref","first-page":"2081\u201399","DOI":"10.1158\/0008-5472.CAN-24-2021","article-title":"Perivascular niche-resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment","volume":"85","author":"Wei","year":"2025","journal-title":"Cancer Res"},{"key":"R37-20260424","doi-asserted-by":"crossref","first-page":"31\u201342","DOI":"10.1016\/j.annonc.2024.09.001","article-title":"A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)","volume":"36","author":"Sakai","year":"2025","journal-title":"Ann Oncol"},{"key":"R38-20260424","doi-asserted-by":"crossref","first-page":"1489045","DOI":"10.3389\/fphar.2024.1489045","article-title":"A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases","volume":"15","author":"Peng","year":"2024","journal-title":"Front Pharmacol"},{"key":"R39-20260424","doi-asserted-by":"crossref","first-page":"1485067","DOI":"10.3389\/fphar.2024.1485067","article-title":"Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess","volume":"15","author":"Ke","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:01:42Z","timestamp":1777057302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000004702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000004702","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"2025-07-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}